BioSpace News Archive

Pfizer Inc. announced the U.S. Food and Drug Administration has granted Fast Track designation to Pfizer’s investigational combination therapy for the treatment of non-alcoholic steatohepatitis with liver fibrosis: ervogastat and clesacostat.

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration has accepted for filing and granted Priority Review of its New Drug Application for omaveloxolone for the treatment of patients with Friedreich’s ataxia.

Eagle Pharmaceuticals, Inc. announced that Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the William Blair 42nd Annual Growth Stock Conference.

Medtronic plc (NYSE: MDT) today announced financial results for its fourth quarter and fiscal year 2022, which ended April 29, 2022.

TELA Bio, Inc. (“TELA”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today announced that the Company will participate in the Jefferies Healthcare Conference on June 8th , 2022.

FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 9 at 1:30pm EDT.

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it has initiated the first of several potential Phase 1b expansion cohorts in its ongoing Phase 1 trial of NX-2127, an orally administered degrader of Bruton’s tyrosine kinase (BTK) with immunomodulatory activity.

Bio-Techne Corporation (NASDAQ: TECH) today announced Advanced Cell Diagnostics (ACD), a brand of Bio-Techne, reached an extraordinary milestone of developing over 40,000 unique RNAscope in situ Hybridization (ISH) probes in over 400 species.

CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced business updates and financial results for the first quarter ended March 31, 2022.

Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced today its financial results for the first quarter ended March 31, 2022.